M
Magí Farré
Researcher at Autonomous University of Barcelona
Publications - 380
Citations - 13435
Magí Farré is an academic researcher from Autonomous University of Barcelona. The author has contributed to research in topics: MDMA & Placebo. The author has an hindex of 58, co-authored 356 publications receiving 11843 citations. Previous affiliations of Magí Farré include Pompeu Fabra University.
Papers
More filters
Journal Article
Cardiovascular and Neuroendocrine Effects and Pharmacokinetics of 3,4-Methylenedioxymethamphetamine in Humans
TL;DR: The cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") were assessed in a double-blind, randomized, crossover, and controlled clinical trial.
Journal ArticleDOI
Effects of differing phenolic content in dietary olive oils on lipids and LDL oxidation--a randomized controlled trial.
Jaume Marrugat,María-Isabel Covas,Montserrat Fitó,Helmut Schröder,Elisabet Miró-Casas,Eva Gimeno,M. Carmen López-Sabater,Rafael de la Torre,Magí Farré +8 more
TL;DR: The hypothesis that virgin olive oil consumption could provide benefits in the prevention of oxidative processes is supported, as dose-dependent changes in oxidative stress markers, and phenolic compounds in urine, were observed with the phenolic content of the olive oil administered.
Journal ArticleDOI
Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans
Rafael de la Torre,Susana Solá,Meritxell Pons,Arnaud Duchon,María Martínez de Lagrán,Magí Farré,Montserrat Fitó,Bessy Benejam,Klaus Langohr,Joan Rodríguez,Mitona Pujadas,Jean Charles Bizot,Aida Cuenca,Nathalie Janel,Silvina Catuara,María Isabel Covas,Henri Bléhaut,Yann Herault,Jean M. Delabar,Mara Dierssen +19 more
TL;DR: EGCG is a promising therapeutic tool for cognitive enhancement in DS, and its efficacy may depend of Dyrk1A inhibition, and plasma homocysteine levels are used as an efficacy biomarker in the human study.
Journal ArticleDOI
Efficacy of antidepressants in substance use disorders with and without comorbid depression A systematic review and meta-analysis
TL;DR: Interestingly, SSRIs do not seem to offer significant advantages compared with tricyclic drugs in substance abuse disorders, and differences both related to individual characteristics and specific antidepressant drugs need to be clarified in future studies.
Journal ArticleDOI
Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project.
Paolo Deluca,Zoe Davey,Ornella Corazza,Lucia Di Furia,Magí Farré,Liv Flesland,Miia Mannonen,Aino Majava,Teuvo Peltoniemi,Manuela Pasinetti,Cinzia Pezzolesi,Norbert Scherbaum,Holger Siemann,Arvid Skutle,Marta Torrens,Peer van der Kreeft,Erik Iversen,Fabrizio Schifano +17 more
TL;DR: Although a high number of novel psychoactive substances have been identified in the 2-year duration of the project, not all have become trends that needed public health response and it is recommended that these monitoring activities are to be continued.